MedPath

WIXELA INHUB

WIXELA INHUB

Approved
DIN Number

02495597

Drug Class

Human

Market Date

Feb 13, 2020

Company
HC

Mylan Pharmaceuticals ULC

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02495597
AIG Number0238341001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
R03AK06 SALMETEROL AND FLUTICASONE
Product Specifications
Dosage FormPowder
Route of AdministrationInhalation
AHFS Classification12:12.08.12
Health Canada Classification

ACTIVE INGREDIENTS (2)

FLUTICASONE PROPIONATEActive
Strength: 100 MCG / ACT
Monograph: FLUTICASONE PROPIONATE
SALMETEROL (SALMETEROL XINAFOATE)Active
Strength: 50 MCG / ACT
Monograph: SALMETEROL (SALMETEROL XINAFOATE)

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.